Market News How it works Learn FAQ
| RCT 0.1111 45.99% | NU 12.415 -18.11% | EWZ 33.695 -20.89% | TGL 0.245 10.61% | BBD 2.875 -29.36% | AZTR 1.75 144.76% | SRTM 0.3361 -21.89% | ITUB 7.655 -20.84% | NVD 3.991 -4.75% | XP 15.635 -48.59% | SHFS 0.0996 -24.77% | SOXL 92.26 10.41% | SPCX 148.545 0.72% | PBR 22.22 -15.06% | CLRO 4.77 46.77% | VALE 11.94 -3.71% | GCDT 0.1424 -19.14% | INTC 91.4822 5.20% | NWGL 0.0865 5.49% | TSLL 10.955 12.24% | CRWV 56.965 5.03% | NVDA 216.08 2.43% | SOXS 47.02 -10.37% | BITO 10.715 -1.06% | NOK 8.7457 7.44% | SGRY 23.2124 47.38% | GPUS 0.1839 8.88% | RWM 14.465 -0.58% | TSLG 5.4768 12.46% | ABEV 2.805 -15.00% | IREN 26.31 5.64% | RBNE 0.1704 -10.32% | JBLU 2.305 -12.19% | INTR 4.505 -37.34% | TQQQ 68.81 3.80% | SPDN 8.485 -0.64% | SBS 4.595 -28.20% | AAL 12.24 1.07% | QID 14.175 -2.58% | TSLA 395.14 6.16% | LUCD 0.5264 28.08% | XTND 2.0901 18.08% | SPRC 1.4801 35.79% | WULF 12.38 9.36% | NFLX 63.145 -4.11% | SID 0.9294 -21.24% | CIFR 7.995 0.69% | SQQQ 38.17 -3.81% | T 21 0.33% | PBR-A 19.54 -16.96%
FGFibroGen, Inc. logo

FibroGen, Inc. (FGEN)

NASDAQ Global Select · Currency in USD
$9.07 ▼ -0.15 (-1.63%)
As of Jan 12, 9:30 AM ET. Market open.

Summary

Previous Close
$9.22
Open
$9.10
Day's Range
$9.02 – $9.21
52 Week Range
$4.85 – $21.95
Volume
29,255
Avg. Volume
33,227
Market Cap
$36.69M
Beta (5Y Monthly)
0.77
PE Ratio (TTM)
0.20
EPS (TTM)
$45.25
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$28.00

Profile: FibroGen, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
225
CEO
Thane Wettig

FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes.

Earnings

DateEst.Actual
Nov 10, 2025-$4.01-$1.61Beat
Aug 11, 2025-$2.25-$3.38Miss
May 12, 2025$0.75$0.05Miss
Mar 17, 2025-$2.00-$4.50Miss
Nov 12, 2024-$7.66-$4.25Beat
Aug 6, 2024-$6.50-$4.00Beat

Analyst view

Consensus price target
$28.00 ▲ +208.7%
Range $28.00 – $28.00
Rating: Hold
Buy 36% · Hold 50% · Sell 14%

Get free alerts on FGEN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.